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Abstract Despite the fact that phosphatidic acid (PtdOH) has
been implicated as a lipid second messenger for nearly a decade,
its intracellular targets have remained unclear. We sought to
investigate how an increase in the level of PtdOH could modulate
phosphatidylinositol 4-phosphate 5-kinase (PIPkin), an enzyme
involved in phosphatidylinositol 4,5-bisphosphate synthesis.
Transfection of porcine aortic endothelial (PAE) cells with
haemagglutinin (HA)-tagged type IK PIPkin followed by
immunofluorescence confocal microscopy revealed the enzyme
to be localised to the plasma membrane. When the transfected
PAE cells were stimulated with lyso-PtdOH, increased PIPkin
activity was found to be associated with HA immunoprecipitates
in an in vitro assay. This PIPkin activation was found to be
greatly reduced by prior treatment of the cells with 1-butanol,
thereby implicating phospholipase D (PLD) as the in vivo
generator of PtdOH. In order to determine if the PtdOH-
dependent activation of type IK PIPkin was dictated by a specific
molecular composition of PtdOH, the wild type murine and
porcine K isoforms of diacylglycerol kinase (DGK) were
individually co-transfected along with type IK PIPkin. Under
these conditions an increase in type IK PIPkin lipid kinase
activity was found in HA immunoprecipitates in an in vitro assay.
No increases in lipid kinase activity were observed when type IK
PIPkin was co-transfected with either the human DGKO isoform
or a kinase-dead mutant of the murine DGKK isoform. These
results provide the first direct evidence for the unification of the
production of saturated/monounsaturated PtdOH (through two
different routes, PLD and DGK) and the in vivo activation of
type IK PIPkin by this lipid second messenger. ß 2000 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
The regulation of the phosphoinositide family of phospho-
lipids requires the balance of phosphoinositide kinases, phos-
phoinositide phosphatases and phospholipases. Phosphatidyl-
inositol 4,5-bisphosphate (PtdIns4,5P2) is a phosphoinositide
which plays a pivotal role in signal transduction mechanisms.
It may be hydrolysed by phosphatidylinositol-speci¢c phos-
pholipase C generating the classical second messengers diac-
ylglycerol (DAG) and inositol 1,4,5-trisphosphate [1] or it
may be phosphorylated by phosphatidylinositol 3-kinase, to
form the more novel lipid second messenger phosphatidylino-
sitol 3,4,5-trisphosphate and other 3-phosphorylated phos-
phoinositides [2]. In addition to PtdIns4,5P2 being a substrate,
it is also a cofactor for a variety of enzymes and plays roles in
intracellular tra⁄cking and reorganisation of the cytoskeleton
[3]. Up to recently, the only route of PtdIns4,5P2 synthesis
known was through the sequential phosphorylation of phos-
phatidylinositol, the last step being catalysed by a 5-kinase.
This 4-phosphate 5-kinase reaction is now known to be cata-
lysed by the type I family of the phosphatidylinositol 4-phos-
phate 5-kinase (PIPkin) superfamily and probably accounts
for over 95% of the total PtdIns4,5P2 synthesis. The type I
family consists of three isoforms, K, L and Q [4^6]. In addition
to the synthesis of PtdIns4,5P2 via the 4-phosphate 5-kinase
pathway, a 5-phosphate 4-kinase reaction exists and is cata-
lysed by the type II PIPkin family consisting of several iso-
forms [5^7]. This route of PtdIns4,5P2 synthesis is not well
understood and it probably contributes to only a very small
proportion of the total PtdIns4,5P2 formed. Finally, the PIP-
kin family is completed with the type III family which are
3-phosphate 5-kinases which are responsible for phosphatidyl-
inositol 3,5-bisphosphate (PtdIns3,5P2) formation [8,9]. In
spite of the de¢nitions ascribed to the type I and type II
PIPkin isoforms in terms of their substrate speci¢cities and
phosphorylated reaction products, in vitro assays using re-
combinant proteins have demonstrated promiscuous enzy-
matic activity [10,11]. Because of this promiscuity, caution
should be exercised when trying to extrapolate these results
to in vivo phosphoinositide metabolism.
During the cloning and biochemical characterisation of the
type I PIPkin family members it was observed that their in
vitro lipid kinase activity was enhanced in the presence of
phosphatidic acid (PtdOH) [4,12^14]. Interest in the lipid sec-
ond messenger PtdOH has been intense as it arises principally
from two major signal transduction pathways, via phospholi-
pase D (PLD) [15,16] and diacylglycerol kinase (DGK) [17^
19]. Despite the fact that a large number of studies have
implicated PtdOH as a regulator of numerous enzymes and
processes [20], very few reports have come up with de¢nitive
answers. We have re-investigated these observations and in
doing so moved to a physiological in vivo model system.
Our results show that PLD- and DGK-derived increased in-
tracellular PtdOH may stimulate the in vivo lipid kinase ac-
tivity of type IK PIPkin and therefore the latter represents a
novel PtdOH e¡ector.
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2. Materials and methods
2.1. Materials
[Q32P]ATP (speci¢c activity 3000 Ci/mmol) and carrier-free
[32P]orthophosphate were purchased from Amersham. Foetal calf se-
rum (FCS), cell culture media and supplements were bought from
Gibco. Silica gel thin layer chromatography (TLC) plates (60 Aî ,
LK6D) were from Whatman. Lyso-PtdOH and phosphatidylinositol
4-monophosphate (PtdIns4P) was purchased from Avanti Polar Lip-
ids. Phosphatidylinositol 3-monophosphate (PtdIns3P) was from Bio-
Mol. Phorbol myristoyl acetate (PMA), PtdIns4,5P2, PtdOH (mixed
fatty acid molecular species, egg yolk) and dioctanoyl-PtdOH (diC8-
PtdOH) were from Sigma. The anti-haemagglutinin (HA) antibody
was purchased from the Berkeley Antibody Company, whereas the
anti-protein disulphide isomerase (PDI) antibody was from StressGen
Biotechnologies. DNA encoding murine type IK PIPkin (a kind gift
from Dr H. Ishihara, University of Tokyo and Prof. Y. Oka, Yama-
guchi University, Japan), murine DGKK, the kinase-dead murine
DGKK mutant, porcine DGKK (a kind gift from Drs H. Kanoh
and F. Sakane, Sapporo Medical University School of Medicine,
Sapporo, Japan) and human DGKO (a kind gift from Dr S.M. Pre-
scott, Huntsman Cancer Center Institute, University of Utah, Salt
Lake City, UT, USA) were subcloned into the pcDNA3 eukaryotic
expression vector. All proteins, except for porcine DGKK, were la-
belled with a 5P-HA tag in order to assess their level of expression by
Western blotting. The level of porcine DGKK expression was moni-
tored by the use of a DGKK antibody (a kind gift from Dr H. Ka-
noh). Authentic radiolabelled standards for strong ion exchange high
performance liquid chromatography (SAX-HPLC) were prepared as
previously described [21]. Salts, organic solvents and other reagents
were of analytical grade and were supplied by Merck.
2.2. Cell culture and transfection
Porcine aortic endothelial (PAE) cells were maintained in mono-
layer cultures in 100 mm diameter petri dishes in Ham’s F12 medium
supplemented with 10% v/v FCS, 2 mM glutamine, 100 U/ml penicil-
lin, 100 Wg/ml streptomycin and 10 mM HEPES. Cells were passaged
twice weekly and plated into 100 mm diameter petri dishes for trans-
fection (20 Wg DNA/107 cells) by electroporation (Gene Pulser, Bio-
Rad). For immuno£uorescence and in vitro kinase assays, cells were
used approximately 15 h after transfection. For cell stimulations, cell
monolayers were washed twice with phosphate-bu¡ered saline (PBS)
10 h after transfection. Thereafter, the cells were left in Ham’s F12
medium containing 0.1% w/v essentially fatty acid-free bovine serum
albumin (BSA) for a further 16 h.
2.3. Immuno£uorescence confocal microscopy
After transfection the cells were grown on coverslips for 15 h. They
were then washed with PBS and ¢xed at 4‡C with 4% w/v para-
formaldehyde in PBS for 20 min followed by blocking with 2% w/v
BSA in PBS for 2 h. All the following incubations and washes were
performed in the bu¡er 0.5% w/v BSA, 0.1% v/v Triton X-100 in PBS.
The incubations with the antibodies were performed at 37‡C in a
moist chamber for 1 h. The anti-HA antibody was detected using a
cy2-linked anti-mouse antibody and the anti-PDI antibody using a
cy3-linked anti-rabbit antibody. The stained cells were observed in a
confocal microscope (Leica).
2.4. Cell stimulation and PIPkin activity measurements
Non-quiescent transfected PAE cells were collected from the petri
dishes by trypsinisation. Pelleted cells were frozen on dry ice before in
vitro kinase assays. Quiescent PAE cells were stimulated with 10 WM
lyso-PtdOH or 100 WM diC8-PtdOH for 10 min. In some experiments,
the cells were pre-incubated (for 15 min) with 30 mM butan-1-ol
before stimulation. After rapid aspiration of the incubation media,
the cell monolayers were rapidly frozen by placing the dishes in a
dry ice/ethanol mixture. The cells were collected by scraping in ice-
cold PBS, followed by their lysis in ice-cold bu¡er containing 150 mM
NaCl, 50 mM NaF, 1% v/v NP-40, 1 mM EDTA, 1 mM orthovana-
date, 10 Wg/ml leupeptin, 10 Wg/ml aprotinin and 1 mM phenyl-
methylsulphonyl £uoride for 15 min. After lysate clearing by centri-
fugation at 14 000 rpm for 15 min at 4‡C in a bench microfuge,
immunoprecipitation of HA-tagged enzymes was performed for 2 h
at 4‡C with 5 Wg anti-HA antibody followed by the addition of Q-bind
Sepharose (Pharmacia) for 1 h at 4‡C. The immunoprecipitates were
washed twice with lysis bu¡er, twice with 500 mM LiCl and twice with
50 mM Tris^HCl, 0.1 mM EDTA pH 7.4 (assay bu¡er). The e¡ects of
PtdOH, diC8-PtdOH and lyso-PtdOH on type IK PIPkin activity was
assessed by adding the lipids as a 10 times concentrate (800 WM, in
5 Wl) prepared by sonication (5 min, room temperature) in assay bu¡-
er. Control preincubations employed sonicated assay bu¡er. PtdIns4P
(the substrate) was prepared as a 10 times concentrate (in 5 Wl) by its
sonication (5 min, at room temperature) into assay bu¡er. Final assay
conditions contained PtdIns4P at 200 WM, ATP at 20 WM, MgCl2 at
10 mM and 10 WCi [Q32P]ATP in a total volume of 50 Wl. Reactions
were performed at room temperature for 15 min before lipid extrac-
tion using CHCl3/MeOH/HCl. The washed CHCl3 phase was either
directly applied to a 1% potassium oxalate-treated TLC plate followed
by its development in propanol-1-ol/2 M acetic acid (2/1, v/v) or
processed for SAX-HPLC (to determine the isomer of PtdInsP2
formed) as previously described [21]. Radioactive spots on the TLC
plates were identi¢ed by autoradiography followed by phosphorimag-
ing analysis (Bio-Rad). The migration of standard authentic non-ra-
dioactive standards applied to all TLC plates was revealed by iodine
staining.
2.5. PLD assay
Quiescent PAE cells in six-well plates were brie£y metabolically
labelled with orthophosphate (100 WCi/ml, 2 h) in phosphate-free cul-
ture medium. After a preincubation with 30 mM 1-butanol, the cells
were stimulated with 100 nM PMA, 10 WM lyso-PtdOH or 100 WM
diC8-PtdOH for 10 min. The overlying medium was rapidly removed
before the incubations were quenched with ice-cold methanol. Total
phospholipids were extracted. Phosphatidylbutanol (PtdBut) was sep-
arated from all other phospholipids by TLC using the solvent system
consisting of chloroform/methanol/acetic acid (65/15/2, v/v). Radio-
active spots on the TLC were identi¢ed by autoradiography followed
by phosphorimaging analysis.
2.6. Western blotting
Ten per cent of the HA immunoprecipitate was mixed with sample
bu¡er, boiled for 5 min and then subjected to SDS^PAGE. After
transfer to a nitrocellulose membrane (Bio-Rad) and blocking, the
membrane was probed with the primarily antibody (anti-HA or
anti-DGKK). After washing, the secondary antibody (anti-horseradish
peroxidase) was added. Chemical visualisation of the immobilised
proteins was achieved by using an ECL kit (Amersham) according
to the recommended procedures.
3. Results and discussion
In order to study the biochemical regulation of type IK
PIPkin activity, our ¢rst goal was to transfect the HA-tagged
form of the enzyme in the adherent PAE cell line. A high level
of expression of HA-tagged type IK PIPkin was found after
approximately 15 h after transfection. Immuno£uorescence
confocal microscopy clearly demonstrated that the HA-tagged
type IK PIPkin was exclusively localised at the plasma mem-
brane (Fig. 1A). No localisation of the HA-tagged type IK
PIPkin was found within the endoplasmic reticulum as a spe-
ci¢c antibody for the endoplasmic reticulum failed to coloc-
alise with the anti-HA antibody (Fig. 1A). These results are in
contrast to those seen in rat kidney ¢broblasts where type IK
PIPkin was seen as ‘nuclear speckles’ free from membrane
structures [22]. Con¢rmation of the strong expression of
HA-tagged type IK PIPkin in PAE cells was also observed
by Western blotting using anti-HA antibodies. Only those
cells transfected with HA-type IK PIPkin expressed a protein
with a molecular weight of approximately 68 kDa correspond-
ing to that of type IK PIPkin [5] (Fig. 1B). When HA immu-
noprecipitates from empty vector- and HA-tagged type IK
PIPkin vector-transfected PAE cells were mixed with
PtdIns4P and [Q32P]ATP, only those cells which had been
transfected with HA-tagged type IK PIPkin were able to phos-
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phorylate PtdIns4P in an in vitro assay (Fig. 1C). In order to
exclude any possibility that the radiolabelled product of the
reaction was not PtdIns4,5P2, the radiolabelled product was
deacylated and subjected to SAX-HPLC. Fig. 1D shows that
the radiolabelled reaction product coincided with an authentic
deglycerated [3H]PtdIns4,5P2 standard and was well separated
from the deglycerated radiolabelled standards PtdIns3,5P2
and phosphatidylinositol 3,4-bisphosphate (PtdIns3,4P2).
When PtdIns3P instead of PtdIns4P was supplied as a sub-
strate in other in vitro lipid kinase assays using HA-tagged
type IK PIPkin immunoprecipitates, PtdIns3,5P2 was con-
¢rmed to be the radiolabelled product (by SAX-HPLC)
Fig. 1. Subcellular localisation, expression and in vitro lipid kinase activity of HA-tagged type IK PIPkin. A: Immuno£uorescence confocal mi-
croscopy of HA-tagged type IK PIPkin-transfected PAE cells. HA-tagged type IK PIPkin staining is shown in green whereas the anti-PDI stain-
ing is in red. Areas of colocalisation would merge to a yellow colour. Two ¢elds are shown. B: Empty vector- or HA-tagged type IK PIPkin-
transfected PAE cells were lysed and HA immunoprecipitates were prepared. 10% of the HA immunoprecipitates were mixed with sample bu¡-
er before boiling for 5 min. Proteins were separated by SDS^PAGE. Western blotting was performed using the primary antibody anti-HA.
C: The remainder of the HA immunoprecipitates were mixed with PtdIns4P and [Q32P]ATP for the in vitro assay. After lipid extraction the ra-
diolabelled products were separated by TLC. The panel shows the part of the TLC plate corresponding to where the authentic PtdIns4,5P2
standard migrated. D: SAX-HPLC analysis of the radiolabelled product from the in vitro lipid kinase activity of HA-tagged type IK PIPkin.
3H radioactivity from the deacylated PtdIns4,5P2 authentic standard is indicated by the open circles whereas the black circles represent the
32P radioactivity from the in vitro kinase radiolabelled deacylated product. The arrows indicate where the deacylated PtdIns3,5P2 authentic
standard (GroPIns3,5P2) and deacylated PtdIns3,4P2 authentic standard (GroPIns3,4P2) migrated in the SAX-HPLC pro¢le. The results shown
in each panel are from a single experiment representative of at least three further independent experiments.
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(data not shown). This observation was identical to that seen
by two other independent laboratories [10,11]. These prelimi-
nary results con¢rmed that we had successfully transfected
type IK PIPkin into PAE cells and that the expressed protein
had functional lipid kinase activity.
Our next objective was to determine if the lipid kinase ac-
tivity of the expressed HA-tagged type IK PIPkin could be
modi¢ed by lipids in an in vitro assay. Fig. 2 indicates that
a commercially available PtdOH preparation (mixed fatty acid
molecular species from egg yolk) was able to stimulate the
lipid kinase activity of type IK PIPkin by approximately 2.1-
fold. A lower fold activation (approximately 1.8 times) was
observed with diC8-PtdOH (Fig. 2). Our PtdOH-dependent
fold stimulation of lipid kinase activity was considerably less
than that reported previously [4,12^14]. These authors used
0.1% v/v Triton X-100 in the assay. We avoided the used of
detergent as this was found to greatly inhibit the basal lipid
kinase activity (data not shown). In contrast to PtdOH, lyso-
PtdOH failed to stimulate lipid kinase activity above that
found in appropriate control incubations (Fig. 2). The results
of these in vitro lipid kinase assays would suggest that acti-
vation of type IK PIPkin requires a lipid species consisting of
at least a structure containing PtdOH and therefore forms a
novel mechanism for the positive modulation of the lipid ki-
nase activity.
In PAE cells, a comprehensive study of the molecular spe-
cies of DAG and the fatty acid composition of PtdOH from
resting and agonist-stimulated cells has been published [23]. In
this study, lyso-PtdOH was shown to deliver its mitogenic
signal by increasing the intracellular PtdOH level solely
through the activation of PLD. Therefore, in order to build
on the observations herein and those elsewhere [4,12^14] of
the stimulatory e¡ect of PtdOH on type IK PIPkin in vitro
lipid kinase activity, we decided to determine if the lipid ki-
nase activity of type IK PIPkin was able to be modulated in
vivo by increasing the intracellular level of PtdOH. When the
HA-tagged type IK PIPkin-transfected PAE cells were stimu-
lated with lyso-PtdOH, approximately a 2.2-fold increase in in
vitro lipid kinase activity was seen (Fig. 3A). This stimulation
in lipid kinase activity was inhibited (by approximately 70%)
by prior treatment of the cells with 1-butanol which is known
to block the production of PtdOH via PLD by converting it
into phosphatidylbutanol through the transphosphatidylation
reaction [15,16]. This result shows for the ¢rst time that ago-
nist-stimulated PtdOH production is able to stimulate the
lipid kinase activity of type IK PIPkin in vivo. When HA-
tagged type IK PIPkin-transfected PAE cells were stimulated
with diC8-PtdOH, a slightly higher increase in lipid kinase
activity (approximately 2.6-fold) was observed when measured
in the in vitro assay (Fig. 3A). It has been reported that
PtdOH can stimulate PLD activity [24]. Therefore, an increase
in endogenous PtdOH may mediate cell stimulation by exo-
genously added diC8-PtdOH. Support for this claim is shown
in the same panel as signi¢cant inhibition (approximately
70%) of stimulated lipid kinase activity was seen when the
Fig. 2. PtdOH but not lyso-PtdOH is able to stimulate the lipid ki-
nase activity of type IK PIPkin in an in vitro assay. PAE cells were
transfected with a vector containing HA-tagged type IK PIPkin.
After lysis, HA immunoprecipitates were prepared. These were then
preincubated with either PtdOH (of mixed fatty acid molecular spe-
cies originating from egg yolk), diC8-PtdOH or lyso-PtdOH before
being mixed with PtdIns4P and [Q32P]ATP for the in vitro assay.
After lipid extraction, the radiolabelled products were separated by
TLC. The radioactivity found within the area where the authentic
unlabelled PtdIns4,5P2 standard migrated was quanti¢ed by phos-
phorimaging. The ¢gure shows the results (mean þ S.D. of duplicate
determinations) of a single experiment which is representative of a
further independent experiment with identical results.
Fig. 3. Type IK PIPkin lipid kinase activity is increased in vivo by
stimulation of PAE cells with lyso-PtdOH and diC8-PtdOH via
PLD. A: PAE cells were transfected with a vector containing HA-
tagged type IK PIPkin and then left to enter a state of quiescence.
Half the dishes of cells were then treated with 30 mM 1-butanol.
Afterwards the cells were stimulated with lyso-PtdOH and diC8-
PtdOH. After freezing the cell monolayers, the cells were collected
by scraping. Thereafter, HA immunoprecipitates were prepared and
mixed with PtdIns4P and [Q32P]ATP for the in vitro assay. After lip-
id extraction, the radiolabelled products were separated by TLC.
The radioactivity found within the area where the authentic unla-
belled PtdIns4,5P2 standard migrated was quanti¢ed by phosphor-
imaging. The panel shows the results (mean þ S.D. of duplicate de-
terminations) of a single experiment which is representative of a
further independent experiment with identical results. B: Non-trans-
fected PAE cells were left to enter a state of quiescence during
which metabolic radiolabelling with orthophosphate was performed
during the last 2 h. The cells were then treated with 30 mM 1-buta-
nol before stimulations with PMA, lyso-PtdOH and diC8-PtdOH.
After quenching the incubations, total phospholipids were extracted
followed by their separation by TLC. The panel shows the part of
the TLC plate corresponding to where the authentic PtdBut stan-
dard migrated. The panel shows the results (mean þ S.D. of dupli-
cate determinations) of a single experiment which is representative
of a further independent experiment with identical results.
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cells were preincubated with 1-butanol prior to their stimula-
tion with diC8-PtdOH. Con¢rmation of the activation of
PLD by diC8-PtdOH is indicated in Fig. 3B. The stimulated
fold increases in PLD activity, as measured by the transphos-
phatidylation reaction, for PMA (positive control), lyso-
PtdOH and diC8-PtdOH were approximately four, three
and two times above control, respectively.
In PAE cells the fatty acid composition of resting and ago-
nist-stimulated PtdOH consists of essentially saturated and
monounsaturated fatty acids [23]. In our in vitro lipid kinase
assays we used a commercial preparation of PtdOH, of mixed
fatty acid composition. The fatty acid analysis of the PtdOH
preparation by gas chromatography/mass spectrometry re-
vealed that it consisted mainly of saturated and monounsatu-
rated fatty acids (palmitic acid, stearic acid and oleic acid)
with some diunsaturated fatty acid (linoleic acid) (Jones and
Me¤rida, unpublished observations). As there were similarities
in the compositions of both the lyso-PtdOH-stimulated
PtdOH accumulation in PAE cells [23] and the PtdOH used
in the in vitro assay, together the results point to the fact that
a saturated/monounsaturated PtdOH may be the preferred
activator of type IK PIPkin in vivo.
In recent years there has been increasing interest in the
DGK family of enzymes and their role in signal transduction
[17^19]. As DGK is a key regulator of the levels of both DAG
and PtdOH, we decided to ask the question if PtdOH-derived
from DGK was also able to stimulate type IK PIPkin lipid
kinase activity in vivo. Because of the scarcity of extracellular
stimuli that stimulate DGK activity, we opted to raise the
level of PAE cell PtdOH by transfection with the K isoform
of porcine DGK or with the recently cloned K isoform of
murine DGK (GenBank accession number AF085219, San-
juan, Jones and Me¤rida, submitted for publication) in combi-
nation with HA-tagged type IK PIPkin. When the HA-tagged
type IK PIPkin was co-transfected with either the porcine K or
murine K DGK isoform, a small increase (approximately 30%
above empty vector control co-transfection) in the type IK
PIPkin lipid kinase activity was found in anti-HA immuno-
precipitates in an in vitro assay (Fig. 4). No such increases in
type IK PIPkin lipid kinase activity in the in vitro assay were
seen in a co-transfection of HA-tagged type IK PIPkin with a
kinase-dead mutant of the murine K DGK isoform (Sanjuan,
Jones and Me¤rida, submitted for publication) (Fig. 4). This
result with the kinase-dead mutant of murine DGKK con¢rms
that the production of PtdOH is essential for the stimulation
of type IK PIPkin lipid kinase activity in vivo rather than a
PtdOH-independent stimulation of the lipid kinase activity
which could be just through association of proteins leading
to changes in their conformation or localisation. Interestingly,
a co-transfection of HA-tagged type IK PIPkin with the hu-
man DGKO isoform did not lead to an increase in type IK
PIPkin lipid kinase activity in HA immunoprecipitates in the
in vitro assay (Fig. 4). In PAE cells there is a large amount of
polyunsaturated DAG (over 25% of total DAG) [23]. In vitro
studies have shown that the DGKO isoform is the only DGK
isoform which shows speci¢city for a DAG containing a poly-
unsaturated fatty acid [25^27]. This speci¢city has been the
subject of a very recent in vivo study con¢rming the selective
removal of solely polyunsaturated DAG species by DGKO in
stably DGKO-transfected PAE cells [28].
Recent progress in the molecular species analysis of the
lipid second messengers DAG and PtdOH has demonstrated
that polyunsaturated DAG is generally the more biologically
active form of this second messenger (compared to saturated/
monounsaturated DAG) whereas in the case of PtdOH the
reverse is true [23,29^32]. This therefore emphasises the fact
that PtdOH produced by the DGKK isoform has a strong
signalling potential, far greater than that produced by
DGKO. These results underline the importance of the gener-
ation of biologically active lipid second messengers for the
propagation of signal transduction pathways and for cross-
talk between otherwise separate pathways. Currently we are
unaware how PtdOH stimulates type IK PIPkin lipid kinase
activity in PAE cells. A change in the localisation of type IK
PIPkin was not seen when the cells were stimulated with lyso-
PtdOH (data not shown). One possibility is that type IK PIP-
kin may associate with other proteins/enzymes such as small
GTPases [33^37], protein kinase CW [38], PLD [39] and type II
phosphatidylinositol 4-kinase [38,39] thereby rapidly regulat-
ing its activity. Another mechanism for type IK PIPkin regu-
lation could be that of covalent modi¢cation such as phos-
phorylation or dephosphorylation events. In summary, our
results show that PtdOH derived either via PLD or via
DGKK may stimulate the activity of type IK PIPkin for the
Fig. 4. Type IK PIPkin lipid kinase activity is increased in vivo by
DGKK isoform-derived PtdOH. A: HA-tagged type IK PIPkin was
co-transfected with either the porcine DGKK isoform, the murine
DGKK isoform, a kinase-dead (kd) murine DGKK isoform or the
human DGKO isoform into PAE cells. After 15 h the cells were
lysed and HA immunoprecipitates were prepared. 10% of the immu-
noprecipitates were mixed with sample bu¡er before boiling for
5 min. Proteins were separated by SDS^PAGE. Western blotting
was performed using the primary antibody anti-HA. The panel
shows the expression of the HA-tagged type IK PIPkin in co-trans-
fected cells from a single experiment which is representative of a
further independent experiment with identical results. B: The re-
mainder of the HA immunoprecipitates were mixed with PtdIns4P
and [Q32P]ATP for the in vitro assay. After lipid extraction the ra-
diolabelled products were separated by TLC. The radioactivity
found within the area where the authentic unlabelled PtdIns4,5P2
standard migrated was quanti¢ed by phosphorimaging. The panel
shows the results of a single experiment which is representative of a
further independent experiment with identical results.
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enhanced production of PtdIns4,5P2 and that the latter en-
zyme is the ¢rst in vivo physiological target identi¢ed for the
lipid second messenger PtdOH.
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